Abstract:PURPOSE Ethnic diversity in cancer research is crucial as race/ethnicity influences cancer incidence, survival, drug response, molecular pathways, and epigenetic phenomena. In 2018, we began a project to examine racial/ethnic diversity in cancer research, with a commitment to review these disparities every 4 years. This report is our second assessment, detailing the present state of racial/ethnic diversity in cancer genomics and clinical trials. METHODS To study racial/ethnic inclusion in cancer genomics, we extracted ethnic records from all data sets available at cBioPortal (n = 125,128 patients) and cancer-related genome-wide association studies (n = 28,011,282 patients) between 2018 and 2022. Concerning clinical trials, we selected studies related to breast cancer (n = 125,518 patients, 181 studies), lung cancer (n = 34,329 patients, 119 studies), and colorectal cancer (n = 40,808 patients, 105 studies). RESULTS In cancer genomics (N = 28,136,410), 3% of individuals lack racial/ethnic registries; tumor samples were collected predominantly from White patients (89.14%), followed by Asian (7%), African American (0.55%), and Hispanic (0.21%) patients and other populations (0.1%). In clinical trials (N = 200,655), data on race/ethnicity are missing for 60.14% of the participants; for individuals whose race/ethnicity was recorded, most were characterized as White (28.33%), followed by Asian (7.64%), African (1.79), other ethnicities (1.37), and Hispanic (0.73). Racial/ethnic representation significantly deviates from global ethnic proportions ( P ≤ .001) across all data sets, with White patients outnumbering other ethnic groups by a factor of approximately 4-6. CONCLUSION Our second update on racial/ethnic representation in cancer research highlights the persistent overrepresentation of White populations in cancer genomics and a notable absence of racial/ethnic information across clinical trials. To ensure more equitable and effective precision oncology, future efforts should address the reasons behind the insufficient representation of ethnically diverse populations in cancer research.

Advancing equity in genomic medicine for rheumatology

Advancing genomics to improve health equity

The importance of functional genomics studies in precision rheumatology

Enhancing the Trajectories of Cancer Health Disparities Research: Improving Clinical Applications of Diversity, Equity, Inclusion, and Accessibility

Advancing health disparities research and improving health for all

Addressing the research gap: access to care hinders genetic discovery in systemic lupus erythematosus patients throughout the African diaspora

Improving access to care for rheumatology services in Canada

Advancing Equity in Rare Disease Research: Insights From the Undiagnosed Disease Network

Toward Equitable Precision Oncology: Monitoring Racial and Ethnic Inclusion in Genomics and Clinical Trials

Advancing diagnosis and research for rare genetic diseases in Indigenous peoples

Clarity for the language of race, ethnicity and genetic ancestry in rheumatology

Preclinical research (on rare diseases): we need to talk about health equity

Principles of clinical genetics for rheumatologists: clinical indications and interpretation of broad-based genetic testing

Overcoming barriers to equitable genomic healthcare

Marginalized measures: The harmonization of diversity in precision medicine research

Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups

The Inclusion of Underrepresented Populations in Cardiovascular Genetics and Epidemiology

African genetic diversity and adaptation inform a precision medicine agenda

Promoting racial equity in digital health: applying a cross-disciplinary equity framework

Precision medicine in rheumatoid arthritis

Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone